相似文献
1
Screening for prostate cancer. How can patients give informed consent?
Can Fam Physician. 1993 Nov;39:2385-90.
2
The impact of informed consent on patient interest in prostate-specific antigen screening.
Arch Intern Med. 1996 Jun 24;156(12):1333-6.
3
What should men know about prostate-specific antigen screening before giving informed consent?
Am J Med. 1998 Oct;105(4):266-74. doi: 10.1016/s0002-9343(98)00257-5.
4
Informed consent. From bodily invasion to the seemingly mundane.
Arch Intern Med. 1996 Jun 24;156(12):1262-3. doi: 10.1001/archinte.156.12.1262.
5
Informed consent for prostate-specific antigen screening.
Urology. 2003 Jan;61(1):13-4. doi: 10.1016/s0090-4295(02)02009-5.
6
Informed consent for prostate cancer screening--a call for equity in medical interventions.
Urology. 2003 Jan;61(1):15-6. doi: 10.1016/s0090-4295(02)02008-3.
7
Screening for prostate cancer: a comparison of urologists and primary care physicians.
South Med J. 1996 Sep;89(9):885-8.
8
Prostate cancer screening: a place for informed consent?
Hosp Pract (Off Ed). 1994 Sep 15;29(9):8, 11-2.
9
Screening for prostate cancer: informing men about their options.
Clin J Oncol Nurs. 2005 Oct;9(5):625-7. doi: 10.1188/05.CJON.625-627.
10
Consent before testing men for prostate cancer--a challenge?
Aust Fam Physician. 2005 Oct;34(10):888.
引用本文的文献
1
[Not Available].
Can Fam Physician. 2017 Sep;63(9):e377-e380.
2
Shared decision making in preventive health care: What it is; what it is not.
Can Fam Physician. 2017 Sep;63(9):682-684.
3
Physician-patient discussions of controversial cancer screening tests.
Am J Prev Med. 2001 Feb;20(2):130-4. doi: 10.1016/s0749-3797(00)00288-9.
4
Prevention. How much harm? How much benefit? 4. The ethics of informed consent for preventive screening programs.
CMAJ. 1996 Aug 15;155(4):377-83.
5
Prevention. How much harm? How much benefit? 1. Influence of reporting methods on perception of benefits.
CMAJ. 1996 May 15;154(10):1493-9.
本文引用的文献
1
In pursuit of the prostate.
Can Fam Physician. 1992 Oct;38:2285-92.
2
Prostate cancer: to screen or not to screen?
BMJ. 1993 Feb 13;306(6875):407-8. doi: 10.1136/bmj.306.6875.407.
3
Natural history and staging of prostate cancer.
Urol Clin North Am. 1984 May;11(2):205-20.
4
Impact of routine screening for adenocarcinoma of the prostate on stage distribution.
J Urol. 1987 Mar;137(3):424-6. doi: 10.1016/s0022-5347(17)44055-9.
5
Prostatic evaluation by transrectal sonography with histopathologic correlation: the echopenic appearance of early carcinoma.
Radiology. 1986 Jan;158(1):97-102. doi: 10.1148/radiology.158.1.3510032.
6
Routine screening for prostate cancer using the digital rectal examination.
Prog Clin Biol Res. 1988;269:87-98.
7
An evaluation of serial digital rectal examinations in screening for prostate cancer.
J Urol. 1988 Dec;140(6):1445-7. doi: 10.1016/s0022-5347(17)42069-6.
8
Deferred treatment for prostate cancer.
Br J Urol. 1988 Sep;62(3):249-53. doi: 10.1111/j.1464-410x.1988.tb04328.x.
9
Total prostatectomy for clinically localized prostatic cancer: long-term results.
J Urol. 1989 Mar;141(3):564-6. doi: 10.1016/s0022-5347(17)40895-0.
10
Natural history of localised prostatic cancer managed by conservative therapy alone.
Lancet. 1988 Mar 5;1(8584):494-7. doi: 10.1016/s0140-6736(88)91294-9.
Zotero 插件